Health Care & Life Sciences » Pharmaceuticals | Wound Management Technologies Inc.

Wound Management Technologies Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
4,148.10
2,278.20
1,340.50
415.70
331.30
Depreciation, Depletion & Amortization
51.70
56.40
60.00
60.90
80.60
Other Funds
2,737.90
701.50
383.40
1,007.60
197.60
Funds from Operations
1,358.60
1,520.20
897.00
652.70
214.30
Changes in Working Capital
463.40
166.50
305.90
243.40
354.20
Net Operating Cash Flow
1,822.00
1,686.70
1,202.90
409.20
139.90
Capital Expenditures
29.90
8.40
5.30
3.00
85.90
Net Investing Cash Flow
29.90
8.40
5.30
3.00
85.90
Cash Dividends Paid - Total
-
10.00
-
-
-
Issuance/Reduction of Debt, Net
1,104.80
68.50
117.10
205.10
194.60
Net Financing Cash Flow
1,850.60
2,174.00
867.10
244.90
144.60
Net Change in Cash
1.30
478.90
341.10
651.10
370.30
Free Cash Flow
1,851.90
1,694.80
1,208.20
406.20
183.80
Change in Capital Stock
745.80
2,252.50
750.00
450.00
50.10

About Wound Management Technologies

View Profile
Address
1200 Summit Avenue
Fort Worth Texas 76102
United States
Employees -
Website http://www.wmgtech.com
Updated 09/14/2018
Wound Management Technologies, Inc. develops, markets and distributes biotechnology products to physicians, hospitals and clinics. It focuses on the distribution of patented collagen product, CellerateRX, Surgical Activated Collagen and HemaQuell which is FDA cleared and reimbursable under medicare part B. he company was founded by Scott A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.